Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.3K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

4.9K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
4.9K
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

11.4K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
11.4K
Substance Use Disorders Affecting Sleep01:24

Substance Use Disorders Affecting Sleep

601
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
601
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

1.6K
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.6K
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

1.3K
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release.

Journal of substance abuse treatment·2022
Same author

Extended release injectable naltrexone before vs. after release: A randomized trial of opioid addicted persons who are in prison.

Journal of substance abuse treatment·2021
Same author

Commentary on Farnum et al.: Agonist maintenance in Ukraine-ambivalence, success and moving forward.

Addiction (Abingdon, England)·2020
Same author

Medication Treatment for Opioid-Addicted Youth-What Are We Waiting for?

The Journal of adolescent health : official publication of the Society for Adolescent Medicine·2020
Same author

Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials.

Addiction science & clinical practice·2020
Same author

Adjunctive psychosocial interventions for opioid use disorder.

The lancet. Psychiatry·2019

Related Experiment Video

Updated: Apr 24, 2026

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

1.8K

Antagonist models for treating persons with substance use disorders.

George E Woody1

  • 1Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Treatment Research Institute, 150 South Independence Mall (W), Philadelphia, PA, 19106, USA, woody@tresearch.org.

Current Psychiatry Reports
|September 4, 2014
PubMed
Summary

Antagonist medications, particularly extended-release naltrexone for opioid dependence, show promise for substance use disorders. While disulfiram is effective for alcohol dependence, patient acceptance and safety concerns limit its use.

More Related Videos

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
07:31

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

7.5K
A Conflict Model of Reward-seeking Behavior in Male Rats
06:11

A Conflict Model of Reward-seeking Behavior in Male Rats

Published on: February 20, 2019

6.8K

Related Experiment Videos

Last Updated: Apr 24, 2026

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

1.8K
Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
07:31

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

7.5K
A Conflict Model of Reward-seeking Behavior in Male Rats
06:11

A Conflict Model of Reward-seeking Behavior in Male Rats

Published on: February 20, 2019

6.8K

Area of Science:

  • Pharmacology
  • Addiction Medicine
  • Psychiatry

Background:

  • Substance use disorders are complex, often involving patient ambivalence towards cessation.
  • Antagonist medications, combined with psychosocial support, offer a strategy to manage this ambivalence.
  • Existing treatments include disulfiram, acamprosate, and naltrexone, with varying efficacy.

Purpose of the Study:

  • To review the current status of antagonist models for substance use disorder treatment.
  • To evaluate the efficacy of specific medications like disulfiram, acamprosate, and naltrexone.
  • To explore emerging treatments such as vaccines for substance use disorders.

Main Methods:

  • Review of clinical data on disulfiram for alcohol dependence.
  • Review of clinical data on acamprosate for alcohol dependence.
  • Review of clinical data on naltrexone for alcohol and opioid dependence.
  • Examination of extended-release formulations and their outcomes.
  • Overview of research on naltrexone for amphetamine dependence.
  • Brief review of vaccine development for substance use disorders.

Main Results:

  • Extended-release naltrexone demonstrates superior results in treating opioid dependence.
  • Disulfiram shows strong effects for alcohol dependence but faces challenges in patient acceptance and safety.
  • Naltrexone and acamprosate offer clinically meaningful, though less robust, effects for alcohol dependence.
  • Naltrexone's efficacy for amphetamine dependence shows mixed findings.
  • Vaccine development presents a promising but early-stage frontier for addiction treatment.

Conclusions:

  • Extended-release naltrexone is highly effective for opioid dependence.
  • Disulfiram's utility for alcohol dependence is constrained by adherence and safety issues.
  • Acamprosate and naltrexone provide valuable options for alcohol use disorder treatment.
  • Novel approaches like vaccines require further development before clinical application.